News & Updates

PARG inhibition slows HCC progression, boosts efficacy of immune checkpoint therapy
PARG inhibition slows HCC progression, boosts efficacy of immune checkpoint therapy
05 Jul 2022

In hepatocellular carcinoma (HCC), poly(ADP-ribose) glycohydrolase (PARG) may serve as an oncogene by modulating PARG/DDB1/c-Myc signaling and be used as a biomarker to identify HCC patients who may derive benefit from anti-PD-1 treatment, suggests a study.

PARG inhibition slows HCC progression, boosts efficacy of immune checkpoint therapy
05 Jul 2022